<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347850">
  <stage>Registered</stage>
  <submitdate>13/12/2011</submitdate>
  <approvaldate>14/12/2011</approvaldate>
  <actrnumber>ACTRN12611001281987</actrnumber>
  <trial_identification>
    <studytitle>Effect of topical mesalazine over adenomas incidence in rectal stumps and ileal pouches of familial adenomatous polyposis patients submitted to colectomy.</studytitle>
    <scientifictitle>In familial adenomatous polyposis patients submitted to total colectomy or proctocolectomy, will the use of 1g per day of mesalazine, as rectal foam, uncontrolled, reduce the incidence of new adenomas in the rectal stumps or ileal pouches?</scientifictitle>
    <utrn>U1111-1126-3718</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adenomas incidence in rectal stumps and ileal pouches</healthcondition>
    <healthcondition>Familial adenomatous polyposis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Mesalazine, 1g per day of rectal foam, for 12months</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>New adenomas (larger than 5mm) incidence in the rectal stumps or ileal pouches, as assessed by endoscopy</outcome>
      <timepoint>At study entry and six and twelve months after mesalazine use</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Dimension, morfology and grade of dysplasia of new adenomas.
Endoscopy will be performed every six months and all polyps larger than 5mm will be removed. Polyp (including adenomas) dimension will be assessed by endoscopy. All polyps will be sent for pathological examination and the morfology and grade of dysplasia of adenomas will be assessed according to the WHO classification.</outcome>
      <timepoint>At study entry and six and twelve months after mesalazine use</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proliferation index of the rectal stump or ileal pouch mucosa.
At each endoscopy, two mucosal biopsies will be performed at each quadrant of the rectal stump or ileal pouch. Proliferation index of the mucosa will be assessed by immunohistochemistry.</outcome>
      <timepoint>At study entry and six and twelve months after mesalazine use</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Nuclear concentration of beta-catenin in colonocytes or enterocytes.
At each endoscopy, two mucosal biopsies will be performed at each quadrant of the rectal stump or ileal pouch.  Nuclear concentration of beta-catenin in colonocytes or enterocytes will be assessed by immunohistochemistry.</outcome>
      <timepoint>At study entry and six and twelve months after mesalazine use</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Familial adenomatous polyposis patients with an identified APC gene mutation, submitted to total colectomy with ileorectal anastomosis or to total proctocolectomy with ileal pouch and with adenomas found in the rectal stump or ileal pouch in the year before study inclusion. Patients have to be under endoscopic surveillance every six months for at least one year prior to study inclusion, with endoscopic removal of all polyps larger than 5mm and pathological exam of all removed polyps.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to give free informed consent; Personal history of inflammatory bowel disease; Cancer or high grade dysplasia in the rectal stump or ileal pouch in the year preceding study inclusion; Renal and/or hepatic failure, acute or chronic; Salycilates allergy; Aspirin, non-steroid anti-inflammatory drugs or COX2 inhibitors use in the three months prior to study inclusion</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/06/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Isadora Rosa</primarysponsorname>
    <primarysponsoraddress>Servico de Gastrenterologia do IPOLFG, EPE
Rua Professor Lima Basto
1099-023 Lisboa</primarysponsoraddress>
    <primarysponsorcountry>Portugal</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, EPE</fundingname>
      <fundingaddress>Rua Professor Lima Basto
1099-023 Lisboa</fundingaddress>
      <fundingcountry>Portugal</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In patients with genetically confirmed diagnosis of familial adenomatous polyposis, and adenomas of the rectal stump or ileal pouch found during surveillance after colectomy, we hypothesized that topical mesalazine may reduce the incidence of new adenomas.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>16/12/2011</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Isadora Alexandra da Luz Rosa</name>
      <address>Servico de Gastrenterologia do IPOLFG, EPE
Rua Professor Lima Basto
1099-023 Lisboa</address>
      <phone>+351217200418</phone>
      <fax />
      <email>isaalr9@netcabo.pt</email>
      <country>Portugal</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Isadora Alexandra da Luz Rosa</name>
      <address>Servico de Gastrenterologia do IPOLFG, EPE
Rua Professor Lima Basto
1099-023 Lisboa</address>
      <phone>+351217200418</phone>
      <fax />
      <email>isaalr9@netcabo.pt</email>
      <country>Portugal</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Isadora Alexandra da Luz Rosa</name>
      <address>Servico de Gastrenterologia do IPOLFG, EPE
Rua Professor Lima Basto
1099-023 Lisboa</address>
      <phone>+351217200418</phone>
      <fax />
      <email>isaalr9@netcabo.pt</email>
      <country>Portugal</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>